fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

ASH 2017: Experts offer guidance on smouldering myeloma

Written by | 17 Jan 2018

Article written by Tom Collins. Interview by Esther Drain. Even as definitions of risk groups in myeloma become more sophisticated, a reasonable way to assess those patients with… read more.

Mixed results for new NHL therapies

Written by | 15 Jan 2018

Professor Stephen Ansell (Mayo Clinic, USA) speaks about harnessing the power of immunotherapy in Non Hodgkin’s Lymphoma.

ASCO 2017: Adjuvant abiraterone has very significant effect on prostate cancer survival

Written by | 14 Aug 2017

Men who have received initial treatment for prostate cancer with abiraterone added to hormone therapy achieved a survival rate 37 per cent higher than those not treated with… read more.

ICML 2017: Highlights

Written by | 30 Jul 2017

Interviewer: Esther Drain Dr Toby Eyre (Oxford),  Professor Anas Younes (MSKCC, USA), Dr Andrew Davies (Southampton) and Dr Graham Collins (Oxford) discuss new data in CAR T cell therapy and the first EZH2 inhibitor, tazemetostat, in… read more.

ICML 2017: How will Hodgkins lymphoma be managed in 2020?

Written by | 11 Jul 2017

By Maria Dalby (article) and Esther Drain (interviews) Not only is the treatment ‘landscape’ in Hodgkin lymphoma (HL) changing rapidly both in the first-line and relapsed/refractory setting, but… read more.

ASH 2017: Hesitation still surrounds use of ‘cure’ word in MM

Written by | 17 Jan 2017

Article written by Tom Collins. Interview by Esther Drain. With technology that allows clinicians to determine minimal residual disease negativity down to the 10-6 level, the word “cure” hangs… read more.

ESMO 2016: True burden of head and neck cancer underestimated (France)

Written by | 16 Jan 2017

by Gary Finnegan A nationwide study of head and neck cancers in France has revealed that the true burden of the disease is underestimated by at least one-third,… read more.

Duloxetine shows efficacy for pain associated with breast cancer treatment

Written by | 19 Dec 2016

By Bruce Sylvester Duloxetine (Cymbalta ®), a widely-used treatment for depression and anxiety, appears to reduce joint pain in postmenopausal women being treated for early stage breast cancer,… read more.

EHA 2016: Consolidation and maintenance therapy for multiple myeloma: is it the new standard? Professor Paul Richardson (Harvard Medical School, Boston, USA) and Professor Maria-Victoria Mateos (Salamanca, Spain) discuss the meta-analysis of OS in myeloma with maintenance therapy presented at ASCO and EHA this year, along with strategies for continuous therapies

Written by | 3 Aug 2016

Consolidation and maintenance therapy for multiple myeloma: is it the new standard?   Professor Antonio Palumbo (University of Turin, Italy) and Professor Paul Richardson (Harvard Medical School, Boston,… read more.

EHA 2016: Preventing clonal evolution in multiple myeloma – evidence from clinical trials. Professor Roman Hájek from the Czech Republic discussed the clinical implications of clonal evolution in multiple myeloma (MM) and summarised the latest clinical data.

Written by | 19 Jul 2016

Preventing clonal evolution in multiple myeloma – evidence from clinical trials by Maria Dalby Professor Roman Hájek from the Czech Republic discussed the clinical implications of clonal evolution… read more.

EHA 2016: How monoclonal antibodies will change the treatment of multiple myeloma. Professor Antonio Palumbo (Torino, Italy) discuss the results of the CASTOR trial and Professor Meletios-Athanasios Dimopoulos (Athens, Greece) discussing POLLUX.

Written by | 15 Jul 2016

How monoclonal antibodies will change the treatment of multiple myeloma  by Maria Dalby   Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France Meletios Dimopoulos, University of Athens School of… read more.

ASCO 2016: Elderly glioblastoma patients achieve longer survival with radiation plus temozolomide

Written by | 5 Jul 2016

by Bruce Sylvester: Researchers from a randomized phase III trial report that addition of temozolomide (Temodar) chemotherapy during short-course radiation therapy, followed by monthly maintenance doses of temozolomide,… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.